{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T15:09:48Z","timestamp":1786374588018,"version":"build-2736575974"},"reference-count":41,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T00:00:00Z","timestamp":1786320000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>X-linked retinitis pigmentosa (XLRP) represents a severe inherited retinal dystrophy associated with pathogenic variants in the retinitis pigmentosa GTPase regulator (RPGR) gene. Adeno-associated virus (AAV)-mediated RPGR gene augmentation is designed to preserve photoreceptor structure and function.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Objectives<\/jats:title>\n                    <jats:p>The purpose of this study was to critically appraise and quantitatively synthesize the efficacy and safety evidence for AAV-RPGR gene therapy in X-linked retinitis pigmentosa.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>Scopus, PubMed, the Cochrane Library, ScienceDirect, and Google Scholar were searched from inception through July 11, 2026. Two reviewers independently screened records, two reviewers assessed risk of bias, and extracted data were verified by a second reviewer. Proportions were synthesized using inverse-variance fixed-effect logit models with a 0.5 continuity correction for zero or all-event cells; DerSimonian-Laird random-effects models were used as sensitivity analyses. Cohort linkage, dose-stratified safety, and overlap-adjusted analyses were performed.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>The search identified 571 records and included 12 clinical reports. Pooled retinal sensitivity improvement was 73.8% (95% confidence interval, 56.0%-86.1%; 25\/33 participants), and pooled visual function improvement was 52.3% (95% confidence interval, 38.0%-66.2%; 28\/52 participants). The pooled adverse-event proportion was 42.6% (95% confidence interval, 27.2%-59.5%; 42\/90 participants), intraocular inflammation was 45.5% (95% confidence interval, 34.6%-56.8%; 36\/81 participants), and intraocular-pressure elevation was 34.9% (95% confidence interval, 24.2%-47.4%; 22\/63 participants). Product-specific dose analyses showed greater inflammatory or ocular serious adverse-event frequencies at higher vector exposure.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusion<\/jats:title>\n                    <jats:p>AAV-RPGR gene therapy demonstrates clinically relevant functional signals across multiple outcome domains with a structured and monitorable ocular safety profile. Cohort-linked synthesis, dose-specific interpretation, standardized outcome definitions, and long-term multinational follow-up provide a rigorous framework for subsequent clinical development.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s12967-026-08709-7","type":"journal-article","created":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T09:44:06Z","timestamp":1786355046000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Efficacy and safety of AAV RPGR gene therapy in X-linked retinitis pigmentosa: a systematic review and meta-analysis"],"prefix":"10.1186","volume":"24","author":[{"given":"Kai-Yang","family":"Chen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hoi-Chun","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chi-Ming","family":"Chan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,10]]},"reference":[{"issue":"9","key":"8709_CR1","doi-asserted-by":"publisher","first-page":"4883","DOI":"10.3390\/ijms23094883","volume":"23","author":"W Liu","year":"2022","unstructured":"Liu W, Liu S, Li P, Yao K. Retinitis pigmentosa: progress in molecular pathology and biotherapeutical strategies. Int J Mol Sci. 2022;23(9):4883.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"8709_CR2","doi-asserted-by":"publisher","first-page":"40","DOI":"10.1186\/1750-1172-1-40","volume":"1","author":"C Hamel","year":"2006","unstructured":"Hamel C. Retinitis pigmentosa. Orphanet J Rare Dis. 2006;1(1):40.","journal-title":"Orphanet J Rare Dis"},{"key":"8709_CR3","doi-asserted-by":"crossref","unstructured":"Cross N, van Steen C, Zegaoui Y, Satherley A, Angelillo L. Retinitis pigmentosa: burden of disease and current unmet needs. Clin Ophthalmol 2022;1993\u20132010.","DOI":"10.2147\/OPTH.S365486"},{"key":"8709_CR4","doi-asserted-by":"crossref","unstructured":"Kamde SP, Anjankar A. Retinitis pigmentosa: pathogenesis, diagnostic findings, and treatment. Cureus 2023;15(10).","DOI":"10.7759\/cureus.48006"},{"issue":"1","key":"8709_CR5","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1186\/s12886-019-1169-z","volume":"19","author":"G Garip","year":"2019","unstructured":"Garip G, Kamal A. Systematic review and meta-synthesis of coping with retinitis pigmentosa: implications for improving quality of life. BMC Ophthalmol. 2019;19(1):181.","journal-title":"BMC Ophthalmol"},{"issue":"8","key":"8709_CR6","doi-asserted-by":"publisher","first-page":"7481","DOI":"10.3390\/ijms24087481","volume":"24","author":"X-T-A Nguyen","year":"2023","unstructured":"Nguyen X-T-A, Moekotte L, Plomp AS, Bergen AA, van Genderen MM, Boon CJF. Retinitis pigmentosa: current clinical management and emerging therapies. Int J Mol Sci. 2023;24(8):7481.","journal-title":"Int J Mol Sci"},{"key":"8709_CR7","doi-asserted-by":"publisher","unstructured":"Chivers M, Li N, Pan F, Wieffer H, Slowik R, Leartsakulpanitch J. The burden of X-linked retinitis pigmentosa on patients and society: a narrative literature review. ClinicoEconomics Outcomes Res 2021;565\u201372. https:\/\/doi.org\/10.1016\/j.ajo.2024.05.034","DOI":"10.1016\/j.ajo.2024.05.034"},{"key":"8709_CR8","doi-asserted-by":"crossref","unstructured":"Yang L, Yin X, Feng L, You D, Wu L, Chen N, Li A, Li G, Ma Z. Novel mutations of RPGR in Chinese retinitis pigmentosa patients and the genotype-phenotype correlation. PLoS ONE 2014;9(1):e85752.","DOI":"10.1371\/journal.pone.0085752"},{"issue":"4","key":"8709_CR9","doi-asserted-by":"publisher","first-page":"1000","DOI":"10.1086\/303091","volume":"67","author":"AJ Mears","year":"2000","unstructured":"Mears AJ, Hiriyanna S, Vervoort R, Yashar B, Gieser L, Fahrner S, Daiger SP, Heckenlively JR, Sieving PA, Wright AF. Remapping of the RP15 locus for X-linked cone-rod degeneration to Xp11. 4-p21. 1, and identification of a de novo insertion in the RPGR exon ORF15. Am J Hum Genet. 2000;67(4):1000\u20133.","journal-title":"Am J Hum Genet"},{"issue":"8","key":"8709_CR10","doi-asserted-by":"publisher","first-page":"1022","DOI":"10.1136\/bjophthalmol-2015-307698","volume":"100","author":"JJL Tee","year":"2016","unstructured":"Tee JJL, Smith AJ, Hardcastle AJ, Michaelides M. RPGR-associated retinopathy: clinical features, molecular genetics, animal models and therapeutic options. Br J Ophthalmol. 2016;100(8):1022\u20137.","journal-title":"Br J Ophthalmol"},{"issue":"3","key":"8709_CR11","doi-asserted-by":"publisher","first-page":"898","DOI":"10.3390\/jcm14030898","volume":"14","author":"NA Pechnikova","year":"2025","unstructured":"Pechnikova NA, Poimenidou M, Iliadis I, Zafeiriou-Chatziefraimidou M, Iaremenko AV, Yaremenko TV, Domvri K, Yaremenko AV. Pre-Clinical and Clinical Advances in Gene Therapy of X-Linked Retinitis Pigmentosa: Hope on the Horizon. J Clin Med. 2025;14(3):898.","journal-title":"J Clin Med"},{"issue":"3","key":"8709_CR12","doi-asserted-by":"publisher","first-page":"1839","DOI":"10.3390\/ijms25031839","volume":"25","author":"PE Sladen","year":"2024","unstructured":"Sladen PE, Naeem A, Adefila-Ideozu T, Vermeule T, Busson SL, Michaelides M, Naylor S, Forbes A, Lane A, Georgiadis. A. AAV-RPGR gene therapy rescues Opsin mislocalisation in a human retinal organoid model of RPGR-associated X-linked retinitis pigmentosa. Int J Mol Sci. 2024;25(3):1839.","journal-title":"Int J Mol Sci"},{"issue":"4","key":"8709_CR13","doi-asserted-by":"publisher","first-page":"255","DOI":"10.1038\/s41576-019-0205-4","volume":"21","author":"C Li","year":"2020","unstructured":"Li C, Samulski RJ. Engineering adeno-associated virus vectors for gene therapy. Nat Rev Genet. 2020;21(4):255\u201372.","journal-title":"Nat Rev Genet"},{"key":"8709_CR14","doi-asserted-by":"publisher","first-page":"0291","DOI":"10.34133\/research.0291","volume":"6","author":"X He","year":"2023","unstructured":"He X, Fu Y, Ma L, Yao Y, Ge S, Yang Z, Fan X. AAV for gene therapy in ocular diseases: progress and prospects. Research. 2023;6:0291.","journal-title":"Research"},{"issue":"9","key":"8709_CR15","doi-asserted-by":"publisher","first-page":"674","DOI":"10.3390\/genes10090674","volume":"10","author":"J Cehajic Kapetanovic","year":"2019","unstructured":"Cehajic Kapetanovic J, McClements ME, de la Martinez-Fernandez C, MacLaren RE. Molecular Strategies for RPGR Gene Therapy. Genes. 2019;10(9):674.","journal-title":"Genes"},{"issue":"8","key":"8709_CR16","doi-asserted-by":"publisher","first-page":"1866","DOI":"10.1016\/j.ymthe.2017.05.004","volume":"25","author":"WA Beltran","year":"2017","unstructured":"Beltran WA, Cideciyan AV, Boye SE, Ye G-J, Iwabe S, Dufour VL, Marinho LF, Swider M, Kosyk MS, Sha J. Optimization of retinal gene therapy for X-linked retinitis pigmentosa due to RPGR mutations. Mol Ther. 2017;25(8):1866\u201380.","journal-title":"Mol Ther"},{"key":"8709_CR17","doi-asserted-by":"publisher","first-page":"122","DOI":"10.1016\/j.ajo.2024.05.034","volume":"267","author":"M Michaelides","year":"2024","unstructured":"Michaelides M, Besirli CG, Yang Y, De Guimaraes TAC, Wong SC, Huckfeldt RM, et al. Phase 1\/2 AAV5-hRKp. RPGR (botaretigene sparoparvovec) gene therapy: safety and efficacy in RPGR-associated X-linked retinitis pigmentosa. Am J Ophthalmol. 2024;267:122\u201334.","journal-title":"Am J Ophthalmol"},{"issue":"14","key":"8709_CR18","doi-asserted-by":"publisher","first-page":"3956","DOI":"10.1093\/hmg\/ddv134","volume":"24","author":"Z Wu","year":"2015","unstructured":"Wu Z, Hiriyanna S, Qian H, Mookherjee S, Campos MM, Gao C, et al. A long-term efficacy study of gene replacement therapy for RPGR-associated retinal degeneration. Hum Mol Genet. 2015;24(14):3956\u201370. https:\/\/doi.org\/10.1093\/hmg\/ddv134, PMID 25877300","journal-title":"Hum Mol Genet"},{"issue":"9","key":"8709_CR19","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1167\/tvst.13.9.18","volume":"13","author":"EE Christou","year":"2024","unstructured":"Christou EE, Josan AS, Cehajic-Kapetanovic J, MacLaren RE. Establishing clinical trial endpoints in selecting patients for RPGR retinal gene therapy. Translational Vis Sci Technol. 2024;13(9):18\u201318.","journal-title":"Translational Vis Sci Technol"},{"key":"8709_CR20","doi-asserted-by":"crossref","unstructured":"Ghoraba HH, Akhavanrezayat A, Karaca I, Yavari N, Lajevardi S, Hwang J, et al. Ocular gene therapy: a literature review with special focus on immune and inflammatory responses. Clin Ophthalmol. 2022;1753\u201377.","DOI":"10.2147\/OPTH.S364200"},{"issue":"3\u20134","key":"8709_CR21","doi-asserted-by":"publisher","first-page":"253","DOI":"10.1089\/hum.2019.297","volume":"31","author":"VL Dufour","year":"2020","unstructured":"Dufour VL, Cideciyan AV, Ye G-j, Song C, Timmers A, Habecker PL, Pan W, Weinstein NM, Swider M, Durham AC. Toxicity and efficacy evaluation of an adeno-associated virus vector expressing codon-optimized RPGR delivered by subretinal injection in a canine model of X-linked retinitis pigmentosa. Hum Gene Ther. 2020;31(3\u20134):253\u201367.","journal-title":"Hum Gene Ther"},{"key":"8709_CR22","doi-asserted-by":"publisher","unstructured":"Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, Shamseer L, Tetzlaff JM, Akl EA, Brennan SE, et al. The PRISMA 2020 statement: an updated guideline for reporting systematic reviews. Syst Reviews. 2021;10(1). https:\/\/doi.org\/10.1186\/s13643-021-01626-4.","DOI":"10.1186\/s13643-021-01626-4"},{"key":"8709_CR23","doi-asserted-by":"publisher","unstructured":"Methley AM, Campbell S, Chew-Graham C, McNally R, Cheraghi-Sohi S. PICO, PICOS and SPIDER: A comparison study of specificity and sensitivity in three search tools for qualitative systematic reviews. BMC Health Serv Res. 2014;14(1). https:\/\/doi.org\/10.1186\/s12913-014-0579-0.","DOI":"10.1186\/s12913-014-0579-0"},{"key":"8709_CR24","doi-asserted-by":"publisher","unstructured":"McGuinness LA, Higgins JPT. Risk-of-bias VISualization (robvis): An R package and Shiny web app for visualizing risk-of-bias assessments. Res Syn Meth. 2021;12(1):55\u201361. https:\/\/doi.org\/10.1002\/jrsm.1411.\u00a0","DOI":"10.1002\/jrsm.1411"},{"key":"8709_CR25","doi-asserted-by":"crossref","unstructured":"Sterne JAC, Hern\u00e1n MA, Reeves BC, Savovi\u0107 J, Berkman ND, Viswanathan M, Henry D, Altman DG, Ansari MT. Boutron, I. ROBINSI: a tool for assessing risk of bias in nonrandomised studies of interventions. bmj 2016;355.","DOI":"10.1136\/bmj.i4919"},{"issue":"1","key":"8709_CR26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1002\/jrsm.1090","volume":"5","author":"MS Corbett","year":"2013","unstructured":"Corbett MS, Higgins JPT, Woolacott NF. Assessing baseline imbalance in randomised trials: implications for the Cochrane risk of bias tool. Res Synthesis Methods. 2013;5(1):79\u201385. https:\/\/doi.org\/10.1002\/jrsm.1090.","journal-title":"Res Synthesis Methods"},{"issue":"3","key":"8709_CR27","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1080\/17439760.2016.1262613","volume":"12","author":"V Clarke","year":"2017","unstructured":"Clarke V, Braun V. Thematic analysis. J Posit Psychol. 2017;12(3):297\u20138.","journal-title":"J Posit Psychol"},{"key":"8709_CR28","doi-asserted-by":"crossref","unstructured":"Borenstein M. Comprehensive meta-analysis software. Systematic reviews in health research: meta\u2010analysis in context 2022;535\u2013548.","DOI":"10.1002\/9781119099369.ch27"},{"issue":"7","key":"8709_CR29","first-page":"2133","volume":"65","author":"DG Birch","year":"2024","unstructured":"Birch DG, Lauer AK, Yang P, Sisk R, Anand R, Curtiss D, Christenson A. Waheed, N. K. Subretinal gene therapy AGTC-501 in X-Linked Retinitis Pigmentosa in the phase 1\/2 horizon study: post-hoc analysis of microperimetry results in the high dose groups. Invest Ophthalmol Vis Sci. 2024;65(7):2133.","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"8709_CR30","first-page":"5446","volume":"64","author":"E Caratzas","year":"2023","unstructured":"Caratzas E, Clark M, Fung A, Yang T, Georgiadis T, Page C, Michaelides M, Minnick P, Steinbach D. Humoral immune response to AAV5RPGR (botaretigene sparoparvovec) gene therapy in RPGRassociated Xlinked retinitis pigmentosa. Invest Ophthalmol Vis Sci. 2023;64(8):5446\u20135446. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"8709_CR31","doi-asserted-by":"publisher","first-page":"354","DOI":"10.1038\/s41591-020-0763-1","volume":"26","author":"J Cehajic-Kapetanovic","year":"2020","unstructured":"Cehajic-Kapetanovic J, Xue K, de la Martinez-Fernandez C, Nanda A, Davies A, Wood LJ, Salvetti AP, Fischer MD, Aylward JW, Barnard AR, et al. Initial results from a first-in-human gene therapy trial on X-linked retinitis pigmentosa caused by mutations in RPGR. Nat Med. 2020;26(3):354\u20139. https:\/\/doi.org\/10.1038\/s41591-020-0763-1.","journal-title":"Nat Med"},{"issue":"9","key":"8709_CR32","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1016\/j.ophtha.2024.02.023","volume":"131","author":"BL Lam","year":"2024","unstructured":"Lam BL, Pennesi ME, Kay CN, Panda S, Gow JA, Zhao G, MacLaren RE, MacLaren R, Aleman T, Birch D, et al. Assessment of Visual Function with Cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa in the Randomized XIRIUS Phase 2\/3 Study. Ophthalmology. 2024;131(9):1083\u201393. https:\/\/doi.org\/10.1016\/j.ophtha.2024.02.023. (acccessed 2024).","journal-title":"Ophthalmology"},{"issue":"8","key":"8709_CR33","first-page":"1479","volume":"62","author":"RE MacLaren","year":"2021","unstructured":"MacLaren RE, Lam BL, Lotery AJ, Stanga PE, Jalil A, Pennesi ME, Birch DG, Kay C, Liu J, Liao E, et al. Visual function improvements with BIIB112 (NSRRPGR) in Xlinked retinitis pigmentosa: XIRIUS (doseexpansion) and XOLARIS (natural disease progression) studies. Invest Ophthalmol Vis Sci. 2021;62(8):1479\u20131479. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"7","key":"8709_CR34","first-page":"3846","volume":"63","author":"M Michaelides","year":"2022","unstructured":"Michaelides M, Xu J, Wang D, Wong P, Fung A, Forbes A, Naylor S, Zeldin R, Parker MA, Weleber R, et al. AAV5RPGR (botaretigene sparoparvovec) gene therapy for Xlinked retinitis pigmentosa (XLRP) demonstrates localized improvements in static perimetry. Invest Ophthalmol Vis Sci. 2022;63(7):3846\u20133846. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"8709_CR35","first-page":"2703","volume":"66","author":"ME Pennesi","year":"2025","unstructured":"Pennesi ME, Stanga P, Birch DG, Anand R, Sisk RA, Fulton AB, Gonzalez E, Grover S, Rachitskaya A, Yang P, et al. Subretinal gene therapy laruzova (AGTC501) for Xlinked retinitis pigmentosa (XLRP): Phase 2 DAWN preliminary month 6 results. Invest Ophthalmol Vis Sci. 2025;66(8):2703\u20132703. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"3","key":"8709_CR36","doi-asserted-by":"publisher","first-page":"275","DOI":"10.1001\/jamaophthalmol.2022.6254","volume":"141","author":"L von Krusenstiern","year":"2023","unstructured":"von Krusenstiern L, Liu J, Liao E, Gow JA, Chen G, Ong T, et al. Changes in retinal sensitivity associated with cotoretigene Toliparvovec in X-Linked Retinitis Pigmentosa with RPGR gene variations. JAMA Ophthalmol. 2023;141(3):275. https:\/\/doi.org\/10.1001\/jamaophthalmol.2022.6254.","journal-title":"JAMA Ophthalmol"},{"key":"8709_CR37","doi-asserted-by":"publisher","DOI":"10.1016\/j.ajo.2024.11.021","author":"P Yang","year":"2024","unstructured":"Yang P, Birch D, Lauer A, Sisk R, Anand R, Pennesi ME, Iannaccone A, Yaghy A, Scaria A, Jung J, et al. Subretinal Gene Therapy Drug AGTC-501 for XLRP Phase 1\/2 Multicenter Study (HORIZON): 24-Month Safety and Efficacy Results. Am J Ophthalmol. 2024. https:\/\/doi.org\/10.1016\/j.ajo.2024.11.021. (acccessed 2025).","journal-title":"Am J Ophthalmol"},{"issue":"7","key":"8709_CR38","first-page":"4399","volume":"63","author":"P Yang","year":"2022","unstructured":"Yang P, Lauer A, Pennesi ME, Birch DG, Spencer R, Sisk R, Iannaccone A, Feinsod M, Goldbaum M. 18 Month Analysis of Macular Structure using Optical Coherence Tomography (OCT) from a Phase 1\/2 Clinical Study of Subretinal Gene Therapy Drug AGTC501 for XLinked Retinitis Pigmentosa. Invest Ophthalmol Vis Sci. 2022;63(7):4399\u2013F0078. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"8","key":"8709_CR39","first-page":"1481","volume":"62","author":"P Yang","year":"2021","unstructured":"Yang P, Lauer A, Pennesi ME, Birch DG, spencer r, Sisk RA, Iannaccone A, Leone E, Halliman D, Ihekoromadu N, et al. Six Month Findings from a Phase 1\/2 Clinical Study of Subretinal Gene Therapy Drug AGTC501 for XLinked Retinitis Pigmentosa Show Clinically Meaningful Improvement in Macular Sensitivity. Invest Ophthalmol Vis Sci. 2021;62(8):1481\u20131481. (acccessed 8).","journal-title":"Invest Ophthalmol Vis Sci"},{"issue":"1","key":"8709_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.3109\/13816810.2010.535889","volume":"32","author":"J Hosch","year":"2011","unstructured":"Hosch J, Lorenz B, Stieger K. RPGR: role in the photoreceptor cilium, human retinal disease, and gene therapy. Ophthalmic Genet. 2011;32(1):1\u201311.","journal-title":"Ophthalmic Genet"},{"issue":"24","key":"8709_CR41","doi-asserted-by":"publisher","first-page":"4840","DOI":"10.1093\/hmg\/ddr423","volume":"20","author":"M Gakovic","year":"2011","unstructured":"Gakovic M, Shu X, Kasioulis I, Carpanini S, Moraga I, Wright AF. The role of RPGR in cilia formation and actin stability. Hum Mol Genet. 2011;20(24):4840\u201350.","journal-title":"Hum Mol Genet"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08709-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08709-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08709-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,8,10]],"date-time":"2026-08-10T14:02:45Z","timestamp":1786370565000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08709-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,10]]},"references-count":41,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8709"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08709-7","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,10]]},"assertion":[{"value":"18 October 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable. This study does not involve human participants, human data, or human tissue.","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable. This study does not involve individual data.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"1023"}}